https://scholars.lib.ntu.edu.tw/handle/123456789/511485
標題: | DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker | 作者: | BANG-BIN CHEN TIFFANY TING-FANG SHIH |
公開日期: | 2014 | 卷: | 20 | 期: | 12 | 起(迄)頁: | 3125-3134 | 來源出版物: | World Journal of Gastroenterology | 摘要: | Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) enables tumor vascular physiology to be assessed. Within the tumor tissue, contrast agents (gadolinium chelates) extravasate from intravascular into the extravascular extracellular space (EES), which results in a signal increase on T1-weighted MRI. The rate of contrast agents extravasation to EES in the tumor tissue is determined by vessel leakiness and blood flow. Thus, the signal measured on DCE-MRI represents a combination of permeability and per-fusion. The semi-quantitative analysis is based on the calculation of heuristic parameters that can be extracted from signal intensity-time curves. These enhancing curves can also be deconvoluted by mathematical modeling to extract quantitative parameters that may reflect tumor perfusion, vascular volume, vessel permeability and angiogenesis. Because hepatocel-lular carcinoma (HCC) is a hypervascular tumor, many emerging therapies focused on the inhibition of angio-genesis. DCE-MRI combined with a pharmacokinetic model allows us to produce highly reproducible and reliable parametric maps of quantitative parameters in HCC. Successful therapies change quantitative parameters of DCE-MRI, which may be used as early indicators of tumor response to anti-angiogenesis agents that modulate tumor vasculature. In the setting of clinical trials, DCE-MRI may provide relevant clinical information on the pharmacodynamic and biologic effects of novel drugs, monitor treatment response and predict survival outcome in HCC patients. ? 2014 Baishideng Publishing Group Co., Limited. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/511485 | ISSN: | 1007-9327 | DOI: | 10.3748/wjg.v20.i12.3125 | SDG/關鍵字: | bevacizumab; biological marker; dexamethasone; floxuridine; sorafenib; sunitinib; thalidomide; vandetanib; vasculotropin; angiogenesis inhibitor; contrast medium; gadolinium pentetate; tumor marker; angiogenesis; article; blood vessel permeability; cancer specific survival; clinical trial (topic); computer assisted tomography; diagnostic imaging; disease course; dynamic contrast enhanced magnetic resonance imaging; experimental model; extravascular extracellular space; human; liver cell carcinoma; overall survival; quantitative analysis; radiodiagnosis; tissue perfusion; treatment response; tumor blood flow; tumor invasion; tumor microenvironment; tumor vascularization; vascular tumor; diagnostic use; image enhancement; liver; liver cell carcinoma; liver tumor; neovascularization (pathology); nuclear magnetic resonance imaging; pathology; perfusion; permeability; procedures; theoretical model; treatment outcome; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Clinical Trials as Topic; Contrast Media; Gadolinium DTPA; Humans; Image Enhancement; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Models, Theoretical; Neovascularization, Pathologic; Perfusion; Permeability; Treatment Outcome; Tumor Markers, Biological |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。